Literature DB >> 10438847

Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.

A H Choi1, M Basu, M M McNeal, J D Clements, R L Ward.   

Abstract

This study was to determine whether individual rotavirus capsid proteins could stimulate protection against rotavirus shedding in an adult mouse model. BALB/c mice were intranasally or intramuscularly administered purified Escherichia coli-expressed murine rotavirus strain EDIM VP4, VP6, or truncated VP7 (TrVP7) protein fused to the 42.7-kDa maltose-binding protein (MBP). One month after the last immunization, mice were challenged with EDIM and shedding of rotavirus antigen was measured. When three 9-microg doses of one of the three rotavirus proteins fused to MBP were administered intramuscularly with the saponin adjuvant QS-21, serum rotavirus immunoglobulin G (IgG) was induced by each protein. Following EDIM challenge, shedding was significantly (P = 0.02) reduced (i.e., 38%) in MBP::VP6-immunized mice only. Three 9-micrograms doses of chimeric MBP::VP6 or MBP::TrVP7 administered intranasally with attenuated E. coli heat-labile toxin LT(R192G) also induced serum rotavirus IgG, but MBP::VP4 immunization stimulated no detectable rotavirus antibody. No protection against EDIM shedding was observed in the MBP::TrVP7-immunized mice. However, shedding was reduced 93 to 100% following MBP::VP6 inoculation and 56% following MBP::VP4 immunization relative to that of controls (P = <0.001). Substitution of cholera toxin for LT(R192G) as the adjuvant, reduction of the number of doses to 1, and challenge of the mice 3 months after the last immunization did not reduce the level of protection stimulated by intranasal administration of MBP::VP6. When MBP::VP6 was administered intranasally to B-cell-deficient microMt mice that made no rotavirus antibody, shedding was still reduced to <1% of that of controls. These results show that mice can be protected against rotavirus shedding by intranasal administration of individual rotavirus proteins and that this protection can occur independently of rotavirus antibody.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438847      PMCID: PMC104284          DOI: 10.1128/JVI.73.9.7574-7581.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus.

Authors:  M M McNeal; M N Rae; R L Ward
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

2.  Development of an improved method for measuring neutralizing antibody to rotavirus.

Authors:  D R Knowlton; D M Spector; R L Ward
Journal:  J Virol Methods       Date:  1991-06       Impact factor: 2.014

3.  Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants.

Authors:  D I Bernstein; V E Smith; D S Sander; K A Pax; G M Schiff; R L Ward
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

4.  Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge.

Authors:  E R Mackow; P T Vo; R Broome; D Bass; H B Greenberg
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

5.  Development of an adult mouse model for studies on protection against rotavirus.

Authors:  R L Ward; M M McNeal; J F Sheridan
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

7.  Active protection against rotavirus infection of mice following intraperitoneal immunization.

Authors:  M M McNeal; J F Sheridan; R L Ward
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

8.  Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea.

Authors:  M E Andrew; D B Boyle; B E Coupar; D Reddy; A R Bellamy; G W Both
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population.

Authors:  M Santosham; G W Letson; M Wolff; R Reid; S Gahagan; R Adams; C Callahan; R B Sack; A Z Kapikian
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

10.  Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles.

Authors:  M M McNeal; M N Rae; J A Bean; R L Ward
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

View more
  29 in total

1.  Functional mapping of protective domains and epitopes in the rotavirus VP6 protein.

Authors:  A H Choi; M Basu; M M McNeal; J Flint; J L VanCott; J D Clements; R L Ward
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Inhibitory effects of bile acids and synthetic farnesoid X receptor agonists on rotavirus replication.

Authors:  Yunjeong Kim; Kyeong-Ok Chang
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

4.  Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity.

Authors:  Sarah E Blutt; Kelly L Warfield; Mary K Estes; Margaret E Conner
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

5.  Prevention of the murine model of biliary atresia after live rotavirus vaccination of dams.

Authors:  Alexander J Bondoc; Mubeen A Jafri; Bryan Donnelly; Sujit K Mohanty; Monica M McNeal; Richard L Ward; Greg M Tiao
Journal:  J Pediatr Surg       Date:  2009-08       Impact factor: 2.545

6.  Immune mediators of rotavirus antigenemia clearance in mice.

Authors:  Glendie Marcelin; Amber D Miller; Sarah E Blutt; Margaret E Conner
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

7.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Rhesus rotavirus VP6 regulates ERK-dependent calcium influx in cholangiocytes.

Authors:  Inna Lobeck; Bryan Donnelly; Phylicia Dupree; Maxime M Mahe; Monica McNeal; Sujit K Mohanty; Greg Tiao
Journal:  Virology       Date:  2016-09-23       Impact factor: 3.616

9.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

10.  Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.

Authors:  Marli S P Azevedo; Lijuan Yuan; Cristiana Iosef; Kyeong-Ok Chang; Yunjeong Kim; Trang Van Nguyen; Linda J Saif
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.